Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Mepolizumab

Details

Files
Generic Name:
Mepolizumab
Project Status:
Complete
Therapeutic Area:
Eosinophilic Granulomatosis with Polyangiitis
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0839-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Submission receivedDecember 19, 2023
Review initiatedDecember 20, 2023
Expert committee meeting (initial)July 04, 2024
Draft recommendation posted for stakeholder feedbackAugust 01, 2024
End of feedback periodAugust 16, 2024
Clarification:

- Reconsideration: minor revisions requested by drug programs

- Request for reconsideration accepted

Final recommendation posted-
Canada's Drug Agency review report(s) postedSeptember 10, 2024

Files

Recommendation and Reasons View PDF
Responses to the Questions From the Drug Programs View PDF
Clinical and Pharmacoeconomic Combined Report View PDF
Patient and Clinician Group Input View PDF
Feedback on Draft Recommendation View PDF

Related Content

Last Updated : December 6, 2024